Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8742634 | 0.99 | PPARG (0.50) | PPARGPPARAHTR7MEN1KMT2A | |
| SCHEMBL9366389 | 0.91 | PPARG (0.53) | PPARGPPARAHTR7MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8742253 | 0.91 | PPARG (0.53) | PPARGPPARAHTR7MEN1KMT2A | |
| SCHEMBL9366593 | 0.89 | PPARG (0.51) | PPARGPPARAHTR7MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8742364 | 0.89 | PPARG (0.50) | PPARGPPARAHTR7MEN1KMT2A | |
| Xaliproden SCHEMBL137094 | 0.88 | SIGMAR1 (0.51) | PPARGPPARAHTR7MEN1KMT2A | |
| Xaliproden SCHEMBL29377982 | 0.88 | SIGMAR1 (0.51) | PPARGPPARAHTR7MEN1KMT2A | |
| SCHEMBL3453738 | 0.87 | PPARG (0.49) | PPARGPPARAHTR7MEN1KMT2A | |
| SCHEMBL6589155 | 0.87 | PPARG (0.50) | PPARGPPARAHTR7MEN1KMT2A | |
| Xaliproden SCHEMBL116721 | 0.87 | SIGMAR1 (0.50) | PPARGPPARAHTR7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | claimed |
| US-6344464-B1 | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | claimed |
| EP-0954311-A1 | USE OF 1- 4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRID-1YL]-2-(6,7-DIMETHOXYNAPHT-2-YL) ETHANE FOR PREPARING MEDICINES FOR THE TREATMENT OF CEREBRAL AND NEURONAL DISORDERS | SANOFI-SYNTHELABO (FR) | 1999-11-10 | — | — | EP | claimed |
| WO-1998033502-A1 | USE OF 1-[4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRID-1YL]-2-(6,7-DIMETHOXYNAPHT-2-YL) ETHANE FOR PREPARING MEDICINES FOR THE TREATMENT OF CEREBRAL AND NEURONAL DISORDERS | SANOFI-SYNTHELABO (FR) | 1998-08-06 | — | — | WO | claimed |
| US-5618822-A | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1997-04-08 | — | — | US | claimed |
| US-7320982-B2 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | US | disclosed |
| US-6693118-B2 | E.G., 1-(2-(6,7-METHYLENEDIOXYNAPHTH-2-YL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE AND 1-2-(4-CYCLOHEXENYLPHENYL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6 -TETRAHYDROPYRIDINE; apoptosis inhibition; treatment of graft rejection or of acute or chronic rheumatoid arthritis | SANOFI-SYNTHELABO (FR) | 2004-02-17 | — | — | US | disclosed |
| EP-1017385-B1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI SYNTHELABO (FR) | 2003-07-16 | — | — | EP | disclosed |
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2002-07-11 | — | — | US | disclosed |
| US-6344464-B1 | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | disclosed |
| US-6342505-B1 | inhibiting apoptosis using xaliproden hydrochloride, or other tetrahydropyridine derivatives | SANOFI-SYNTHELABO (FR) | 2002-01-29 | — | — | US | disclosed |
| CN-1245427-A | Use of 1- [ 4- (3-trifluoromethylphenyl) -1, 2,3, 6-tetrahydropyridin-1-yl ] -2- (6, 7-dimethoxynaphthalen-2-yl) ethane for preparing a medicament for the treatment of cerebral and neuronal disorders | SANOFI SYNTHESIS LAB (FR) | 2000-02-23 | — | — | CN | disclosed |
| EP-0954311-A1 | USE OF 1- 4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRID-1YL]-2-(6,7-DIMETHOXYNAPHT-2-YL) ETHANE FOR PREPARING MEDICINES FOR THE TREATMENT OF CEREBRAL AND NEURONAL DISORDERS | SANOFI-SYNTHELABO (FR) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998033502-A1 | USE OF 1-[4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRID-1YL]-2-(6,7-DIMETHOXYNAPHT-2-YL) ETHANE FOR PREPARING MEDICINES FOR THE TREATMENT OF CEREBRAL AND NEURONAL DISORDERS | SANOFI-SYNTHELABO (FR) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998033502-A1 | USE OF 1-[4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRID-1YL]-2-(6,7-DIMETHOXYNAPHT-2-YL) ETHANE FOR PREPARING MEDICINES FOR THE TREATMENT OF CEREBRAL AND NEURONAL DISORDERS | SANOFI-SYNTHELABO (FR) | 1998-08-06 | — | — | WO | disclosed |
| US-5618822-A | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1997-04-08 | — | — | US | disclosed |
| US-5618822-A | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1997-04-08 | — | — | US | disclosed |
| EP-0458697-B1 | N-substituted trifluoromethylphenyl tetrahydropyridines, process for their preparation, intermediates and pharmaceutical preparations containing them | SANOFI ELF (FR) | 1994-07-27 | — | — | EP | disclosed |
| EP-0458697-A1 | N-substituted trifluoromethylphenyl tetrahydropyridines, process for their preparation, intermediates and pharmaceutical preparations containing them | ELF SANOFI (FR) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | PPARG 2860/4885PPARA 1980/4885HTR7 2062/4885 |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | PPARG 3146/4885PPARA 2134/4885HTR7 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.